This was the stock's third consecutive day of gains.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...
Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...
Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings ...
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
13don MSN
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Zacks.com on MSN2d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback